CL2015002113A1 - Compuestos de azetidinloxifenilpirrolidina - Google Patents

Compuestos de azetidinloxifenilpirrolidina

Info

Publication number
CL2015002113A1
CL2015002113A1 CL2015002113A CL2015002113A CL2015002113A1 CL 2015002113 A1 CL2015002113 A1 CL 2015002113A1 CL 2015002113 A CL2015002113 A CL 2015002113A CL 2015002113 A CL2015002113 A CL 2015002113A CL 2015002113 A1 CL2015002113 A1 CL 2015002113A1
Authority
CL
Chile
Prior art keywords
compounds
azetidinloxyphenylpyrrolidine
azetidinyloxyphenylpirrolidine
oab
pde4
Prior art date
Application number
CL2015002113A
Other languages
English (en)
Inventor
Gary G Deng
Danwen Huang
Joshua O Odingo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2015002113A1 publication Critical patent/CL2015002113A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

COMPUESTOS DERIVADOS DE AZETIDINILOXIFENILPIRROLIDINA, INHIBIDORES SELECTIVOS DE LA FOSFODIESTERASA 4 (PDE4); COMPOSICION FARMACEUTICA QUE LOS COMPRENDE; Y SU USO PARA EL TRATAMIENTO DE LA VEJIGA SOBRERREACTIVA (OAB).
CL2015002113A 2013-03-13 2015-07-29 Compuestos de azetidinloxifenilpirrolidina CL2015002113A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361778546P 2013-03-13 2013-03-13

Publications (1)

Publication Number Publication Date
CL2015002113A1 true CL2015002113A1 (es) 2016-01-15

Family

ID=50382705

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002113A CL2015002113A1 (es) 2013-03-13 2015-07-29 Compuestos de azetidinloxifenilpirrolidina

Country Status (40)

Country Link
US (3) US9034864B2 (es)
EP (2) EP2970222B1 (es)
JP (2) JP6017708B2 (es)
KR (2) KR101702797B1 (es)
CN (2) CN109336865A (es)
AP (1) AP3850A (es)
AR (1) AR095015A1 (es)
AU (1) AU2014241444B2 (es)
BR (1) BR112015020222B1 (es)
CA (1) CA2899806C (es)
CL (1) CL2015002113A1 (es)
CR (1) CR20150417A (es)
CY (1) CY1120142T1 (es)
DK (1) DK2970222T3 (es)
DO (1) DOP2015000176A (es)
EA (1) EA026631B1 (es)
ES (1) ES2616470T3 (es)
HK (1) HK1212695A1 (es)
HR (1) HRP20170080T1 (es)
HU (1) HUE032235T2 (es)
IL (1) IL240904B (es)
JO (1) JO3264B1 (es)
LT (1) LT2970222T (es)
MA (1) MA38410B1 (es)
ME (1) ME02592B (es)
MX (1) MX2015012579A (es)
MY (1) MY180006A (es)
NZ (1) NZ710481A (es)
PE (1) PE20151669A1 (es)
PH (1) PH12015502032A1 (es)
PL (1) PL2970222T3 (es)
PT (1) PT2970222T (es)
RS (1) RS55594B1 (es)
SG (2) SG10201609717YA (es)
SI (1) SI2970222T1 (es)
TN (1) TN2015000384A1 (es)
TW (1) TWI617553B (es)
UA (1) UA115583C2 (es)
WO (1) WO2014159012A1 (es)
ZA (1) ZA201505417B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI617553B (zh) * 2013-03-13 2018-03-11 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
WO2016033776A1 (en) * 2014-09-04 2016-03-10 Eli Lilly And Company Crystalline (2s) -3- [ (3s, 4s) -3- [ (1r) -1-hydroxyethyl] -4- (4-methoxy-3- { [1- (5-methylpyridin-2-yl) azetidin-3-yl] oxy} phenyl) -3-methylpyrrolidin-1-yl] -3-oxopropane-1, 2-diol
TW201625591A (zh) * 2014-09-12 2016-07-16 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物
CN111333637B (zh) * 2018-12-18 2022-07-29 武汉人福创新药物研发中心有限公司 苯基吡咯烷类衍生物及其制备方法
CN111333625B (zh) * 2018-12-18 2022-10-18 武汉人福创新药物研发中心有限公司 苯基吡咯烷类化合物及其用途
AU2019408336B2 (en) * 2018-12-18 2022-03-10 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Phenylpyrrolidine compound and use thereof
WO2021036953A1 (zh) * 2019-08-23 2021-03-04 湖北生物医药产业技术研究院有限公司 苯基吡咯烷类化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
JPH07300455A (ja) * 1994-03-08 1995-11-14 Mitsubishi Chem Corp ３−フェニルピロリジン誘導体
DE19601938A1 (de) * 1996-01-12 1997-07-17 Schering Ag Neue Phosphodiesteraseinhibitoren
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US6258833B1 (en) 1999-12-23 2001-07-10 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
OA12542A (en) * 2001-01-31 2006-06-05 Pfizer Prod Inc Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4isozymes.
BRPI0616633A2 (pt) 2005-09-29 2011-06-28 Bayer Healthcare Ag inibidores de pde e combinações dos mesmos para o tratamento de transtornos urológicos
TW201206440A (en) 2010-04-28 2012-02-16 Astellas Pharma Inc Prophylactic or therapeutic agent for diseases associated with pains in urinary organs
MX2012013127A (es) 2010-05-13 2012-11-30 Amgen Inc Compuestos heteroariloxiheterociclilo como inhibidores pde10.
TWI617553B (zh) * 2013-03-13 2018-03-11 美國禮來大藥廠 吖丁啶基氧苯基吡咯啶化合物

Also Published As

Publication number Publication date
SG10201609717YA (en) 2017-01-27
LT2970222T (lt) 2017-03-27
CY1120142T1 (el) 2018-12-12
PH12015502032A1 (en) 2016-01-18
DK2970222T3 (en) 2017-02-27
US9604967B2 (en) 2017-03-28
MY180006A (en) 2020-11-19
CN105051034B (zh) 2019-05-21
CR20150417A (es) 2015-09-16
AP2015008699A0 (en) 2015-09-30
JP6204557B2 (ja) 2017-09-27
CA2899806A1 (en) 2014-10-02
IL240904B (en) 2019-02-28
NZ710481A (en) 2020-08-28
EP3168216A1 (en) 2017-05-17
RS55594B1 (sr) 2017-06-30
US9266859B2 (en) 2016-02-23
CN109336865A (zh) 2019-02-15
DOP2015000176A (es) 2015-11-15
EA201591498A1 (ru) 2015-12-30
SG11201507501YA (en) 2015-10-29
ES2616470T3 (es) 2017-06-13
PE20151669A1 (es) 2015-11-12
US20160122322A1 (en) 2016-05-05
BR112015020222A8 (pt) 2018-01-23
KR20150119077A (ko) 2015-10-23
ZA201505417B (en) 2022-09-28
HRP20170080T1 (hr) 2017-03-10
PL2970222T3 (pl) 2017-06-30
BR112015020222B1 (pt) 2020-07-14
MA38410B1 (fr) 2016-09-30
HK1212695A1 (zh) 2016-06-17
EP2970222A1 (en) 2016-01-20
IL240904A0 (en) 2015-10-29
TWI617553B (zh) 2018-03-11
TW201522327A (zh) 2015-06-16
US9034864B2 (en) 2015-05-19
KR20170013411A (ko) 2017-02-06
JP6017708B2 (ja) 2016-11-02
EP2970222B1 (en) 2016-12-21
JP2016216517A (ja) 2016-12-22
HUE032235T2 (en) 2017-09-28
ME02592B (me) 2017-06-20
SI2970222T1 (sl) 2017-02-28
KR101745304B1 (ko) 2017-06-08
UA115583C2 (uk) 2017-11-27
WO2014159012A9 (en) 2014-12-18
AP3850A (en) 2016-09-30
CA2899806C (en) 2017-07-18
MA38410A1 (fr) 2016-02-29
PT2970222T (pt) 2017-02-08
AU2014241444B2 (en) 2016-04-07
KR101702797B1 (ko) 2017-02-06
BR112015020222A2 (pt) 2017-07-18
WO2014159012A1 (en) 2014-10-02
AU2014241444A1 (en) 2015-08-06
MX2015012579A (es) 2016-01-20
US20140275002A1 (en) 2014-09-18
EA026631B1 (ru) 2017-04-28
US20150133423A1 (en) 2015-05-14
TN2015000384A1 (en) 2017-01-03
JP2016510759A (ja) 2016-04-11
CN105051034A (zh) 2015-11-11
AR095015A1 (es) 2015-09-16
JO3264B1 (ar) 2018-09-16

Similar Documents

Publication Publication Date Title
CO2018005369A2 (es) Inhibidores triazol de acc y usos de los mismos
CL2017000654A1 (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CL2016000925A1 (es) Inhibidores de bromodominio
CO2018000631A2 (es) Compuestos bicíclicos como inhibidores de atx
CL2017000240A1 (es) Compuestos activos hacia bromodominios
CL2016002877A1 (es) Compuestos de 2-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y métodos de uso de los mismos.
CO2018000668A2 (es) Nuevos compuestos bicíclicos como inhibidores duales de atx/ca
CL2016000807A1 (es) Amino heteroarilo benzamidas como inhibidores de quinasa.
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
CR20150462A (es) Inhibidores de erk y sus usos
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
CL2015001377A1 (es) Inhbibidores de bmi-1 primidinas sustituidas inversas
CR20170384A (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
CL2015003280A1 (es) Derivados de benzimidazol como inhibidores de bromodominio
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
DOP2015000274A (es) Compuestos químicos
CL2015002113A1 (es) Compuestos de azetidinloxifenilpirrolidina
CO2017011151A2 (es) Nuevos compuestos bicíclicos como inhibidores de la atx
DOP2015000219A (es) Compuestos de heteroarilo y sus usos
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
DK3582780T3 (da) Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
UY35500A (es) Indazoles sustituidos con heteroarilo
CL2014002880A1 (es) Compuestos derivados de heterociclos nitrogenados o sus sales, inhibidores selectivos de la pde2a; medicamento que los comprende; y su uso para la profilaxis y tratamiento de la esquizofrenia.